Prelude Therapeutics Incorporated (PRLD) Stock Grade

About Prelude Therapeutics Incorporated's fundamentals

Prelude Therapeutics is a clinical-stage biotechnology company with a market capitalization of $161.9 million that is currently unprofitable, reporting a net loss and a net margin of -819.6% in its latest annual statement. The company has demonstrated strong revenue growth of 73.4% year-over-year, indicating expanding business activity as it advances its pipeline. As a pre-profitability biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not pay dividends. Investors should note that biotech companies at this stage typically operate at losses while investing heavily in research and development.